Chiesi is driven by a deep passion to make life better for others. For over 90 years we’ve been dedicated to developing innovative treatments, currently focused on respiratory health, rare diseases, neonatalogy and specialty care.
At our core, we’re here to help people live healthier and better lives, doing so in a sustainable way, as we believe that caring for people, the planet and future generations are deeply connected.
Highlights: David Khougazian appointed Group Chief Executive Officer to lead Chiesi's next phase of innovation-driven growth, effective 15 October 2026. Bringing over 25 years of international healthcare leadership experience and a strong track record in innovation and transformation, David joins…
HIGHLIGHTS H1 2026 revenues of €1.89 billion, up + 3.6% at CER versus H1 2025, driven by growth in the inhaled triple therapy portfolio and strong momentum in the rare diseases therapeutic area Continued investment in innovation with €426 million invested in R&D (22.5% of sales) Completed strategic…
Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been…
Key Highlights This European Authorisation reinforces Chiesi’s commitment to provide a broad range of formulations and devices to asthma patients. NEXThaler® is a dry powder inhaler (DPI), specifically designed for Chiesi’s extrafine formulations. With the addition of the DPI in the asthma…
PARMA, Italy – June 5, 2026 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that the European Commission (EC) has approved lomitapide capsules for use in children 5…
Parma, Italy and Framingham, Mass., USA – 11 June, 2026 – Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. (“KalVista”). KalVista is now part of Chiesi Group…
Highlights: Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and responsible governance across generations Maria Paola Chiesi is appointed Chair, the first woman in this role; aims to reinforce sustainability as an…
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s…
Highlights: Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs.…
International biopharmaceutical leader accelerates digital transformation with AI-powered customer engagement, unified data, and next-generation integration capabilities APRIL 20, 2026 – Chiesi Group, an international biopharmaceutical group, has selected Salesforce’s Agentforce Life Sciences for…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
